Genitourinary Cancer

3:45
Updates on immunotherapy options for metastatic urothelial carcinoma
Kirollos Hanna
3:50
Recommendations for the treatment of muscle and non-muscle invasive urothelial carcinoma
Kirollos Hanna
2:12
Looking towards the future: what is in store for the treatment of bladder cancer?
Kirollos Hanna
1:49
HOPA 2018 updates on urothelial carcinoma: what is new?
Kirollos Hanna
2:06
A golden age for bladder cancer publications
Andrea Apolo
0:44
Unmet needs in bladder cancer in the immunotherapy era
Andrea Apolo
1:14
How can we continue the success of checkpoint inhibitors for bladder cancer treatment?
Andrea Apolo
1:03
POUT trial: a new standard of care for upper tract urothelial carcinoma
Alison Birtle
2:11
Treatment options for patients with bladder cancer, is bladder removal always necessary?
Alison Birtle
1:08
APF in prostate cancer patients following radical prostatectomy: what happens next?
Adam Dicker
2:01
Case-based debate: is there evidence for local treatment in oligometastatic prostate cancer?
Adam Dicker
1:48
What does the 2-year follow-up tell us about the use of pembrolizumab for advanced bladder cancer?
Rob Jones
1:33
Promising POUT: perioperative chemotherapy for upper tract urothelial cancer
Rob Jones
2:02
TKI and checkpoint inhibitor combinations for kidney cancer: the IMmotion151 trial
Rob Jones
2:43
Pembrolizumab: defining standards of care in urothelial cancer
Rob Jones
2:27
How will new NSAAs impact clinical practice in prostate cancer?
Neal Shore
VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJOncology is intended for healthcare professionals